BR112017013170A2 - enxerto de ciclodextrina por ligações amida a um éter ácido hialurônico reticulado e usos do mesmo - Google Patents

enxerto de ciclodextrina por ligações amida a um éter ácido hialurônico reticulado e usos do mesmo

Info

Publication number
BR112017013170A2
BR112017013170A2 BR112017013170A BR112017013170A BR112017013170A2 BR 112017013170 A2 BR112017013170 A2 BR 112017013170A2 BR 112017013170 A BR112017013170 A BR 112017013170A BR 112017013170 A BR112017013170 A BR 112017013170A BR 112017013170 A2 BR112017013170 A2 BR 112017013170A2
Authority
BR
Brazil
Prior art keywords
hyaluronic acid
cross
linked hyaluronic
acid ether
amide bonded
Prior art date
Application number
BR112017013170A
Other languages
English (en)
Inventor
Säwén Elin
Boiteau Jean-Guy
Original Assignee
Galderma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Sa filed Critical Galderma Sa
Publication of BR112017013170A2 publication Critical patent/BR112017013170A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/738—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates

Abstract

um produto de ácido hialurônico está compreendendo um ácido hialurônico reticulado e uma ou mais moléculas de ciclodextrina. o ácido hialurônico é reticulado por ligações éter, e a uma ou mais moléculas de ciclodextrina são enxertadas no ácido hialurônico reticulado por ligações amida, preferivelmente usando um reagente de acoplamento baseado em triazina.
BR112017013170A 2014-12-18 2015-12-17 enxerto de ciclodextrina por ligações amida a um éter ácido hialurônico reticulado e usos do mesmo BR112017013170A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14198793 2014-12-18
PCT/EP2015/080346 WO2016097211A1 (en) 2014-12-18 2015-12-17 Grafting of cyclodextrin by amide bonds to an ether cross-linked hyaluronic acid and uses thereof

Publications (1)

Publication Number Publication Date
BR112017013170A2 true BR112017013170A2 (pt) 2018-01-02

Family

ID=52272864

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017013170A BR112017013170A2 (pt) 2014-12-18 2015-12-17 enxerto de ciclodextrina por ligações amida a um éter ácido hialurônico reticulado e usos do mesmo

Country Status (11)

Country Link
US (1) US10533061B2 (pt)
EP (1) EP3233928A1 (pt)
JP (1) JP2018506603A (pt)
KR (1) KR20170133315A (pt)
CN (1) CN107428851A (pt)
AU (1) AU2015367377A1 (pt)
BR (1) BR112017013170A2 (pt)
CA (1) CA2970853A1 (pt)
MX (1) MX2017008105A (pt)
RU (1) RU2017124620A (pt)
WO (1) WO2016097211A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3156044A1 (en) 2015-10-16 2017-04-19 Merz Pharma GmbH & Co. KGaA In situ cross-linkable polysaccharide compositions and uses thereof
WO2017220622A1 (en) 2016-06-23 2017-12-28 Galderma S.A. Cyclodextrin-grafted cross-linked hyaluronic acid complexed with active drug substances and uses thereof
CN106491526B (zh) * 2016-11-14 2019-03-22 暨南大学 一种药物缓释型复合滴眼液及其制备方法与应用
US20230192931A1 (en) * 2017-03-02 2023-06-22 Osaka University Host-group-containing polymerizable monomer, polymer material, method for producing same, and clathrate compound and method for producing same
WO2019002369A1 (en) * 2017-06-28 2019-01-03 Nestlé Skin Health Sa GLYCOSAMINOGLYCAN HYDROGEL WITH DEXTRANE OR GRAFT CYCLODEXTRIN
KR101899254B1 (ko) * 2017-07-07 2018-09-14 서울대학교산학협력단 흡착용 사이클로덱스트린-함유 화합물 및 그의 제조방법
WO2020127407A1 (en) 2018-12-19 2020-06-25 Merz Pharma Gmbh & Co. Kgaa Aldehyde-modified hyaluronic acid, method for preparing same and applications thereof
CN110408272A (zh) * 2019-07-05 2019-11-05 浙江大学 一种基于主客体作用制备光动力抗菌涂层的方法及其产品和应用
CN115417914A (zh) * 2019-10-11 2022-12-02 润辉生物技术（威海）有限公司 一种乙酰透明质酸寡肽及其制备与应用方法
CN111494648B (zh) * 2020-05-14 2021-10-22 清华大学 润滑载药纳米球、药物及其制备方法
CN112480483B (zh) * 2020-11-27 2022-02-01 华熙生物科技股份有限公司 一种依克多因-透明质酸复合凝胶的制备方法及所得产品
CN112472672B (zh) * 2020-11-30 2022-01-25 西安交通大学 一种多肽-多糖接枝共聚物基铂类纳米前药及制备方法和应用
CN115463109B (zh) * 2022-09-24 2023-07-14 重庆医科大学 一种仿生融合膜包裹尿酸酶和过氧化氢酶纳米粒及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827937A (en) 1995-07-17 1998-10-27 Q Med Ab Polysaccharide gel composition
JP3847405B2 (ja) 1997-03-11 2006-11-22 財団法人野口研究所 天然糖鎖を側鎖に有するシクロデキストリン誘導体とその製造法、及び中間体
WO2014055532A2 (en) 2012-10-02 2014-04-10 Allergan, Inc. Dermal filler hydrogels with vitamin a/cyclodextrin inclusion complexes
WO2015181365A1 (en) 2014-05-29 2015-12-03 Galderma S.A. Cyclodextrin-grafted hyaluronic acid crosslinked with dextran and uses thereof
WO2015181366A1 (en) 2014-05-29 2015-12-03 Galderma S.A. Cross-linked polymer mixture of hyaluronic acid and dextran grafted with cyclodextrins and uses thereof

Also Published As

Publication number Publication date
KR20170133315A (ko) 2017-12-05
WO2016097211A1 (en) 2016-06-23
JP2018506603A (ja) 2018-03-08
AU2015367377A1 (en) 2017-07-20
EP3233928A1 (en) 2017-10-25
CA2970853A1 (en) 2016-06-23
US20180265600A1 (en) 2018-09-20
RU2017124620A (ru) 2019-01-21
CN107428851A (zh) 2017-12-01
US10533061B2 (en) 2020-01-14
MX2017008105A (es) 2018-03-06

Similar Documents

Publication Publication Date Title
BR112017013170A2 (pt) enxerto de ciclodextrina por ligações amida a um éter ácido hialurônico reticulado e usos do mesmo
MX2019003489A (es) Moleculas del receptor de envolvimiento quimerico.
CY1122398T1 (el) Συνδυαστικες θεραπειες με αντισωματα anti-cd38
MX2016015364A (es) Acido hialurónico entrelazado injertado con dextrán.
MX2022008781A (es) Anticuerpos que se unen a interleucina 8 (il-8) y sus usos.
MX2020007266A (es) Moleculas del receptor quimerico de engullido y metodos de uso.
MD3827845T2 (ro) Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
BR112016018408A2 (pt) moléculas de anticorpo à lag-3 e usos das mesmas
WO2017091683A8 (en) Antibody molecules to april and uses thereof
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
NZ735607A (en) Cd20 binding molecules and uses thereof
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA202092435A2 (ru) Моноклональные антитела против bcma
EP4299595A3 (en) Compositions and methods related to engineered fc constructs
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201691991A1 (ru) Мультиспецифические антитела
EA201690314A1 (ru) Анти-garp-белок и его применения
MX2016016886A (es) Anticuerpos anti-axl.
PH12018550160A1 (en) NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
MX2019006406A (es) Exopolisacaridos y usos de los mismos.
MX2017007381A (es) Miembros de union para homologo del oncogen de fibrosarcoma musculoadoneurotico (c-maf) humano.
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
TR201900124T4 (tr) Dispersiyon Reçineleri
BR112016029207A2 (pt) resinas de polietileno
BR112017019207A2 (pt) recuperação e/ou reutilização de catalisador de paládio após acoplamento de suzuki

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]